{"entity":{"id":"nuvalent","kind":"company","name":"Nuvalent","aka":[],"tldr":"Designer of cleaner kinase inhibitors; zidesamtinib (ROS1) approved July 2026, neladalkib (ALK) next.","summary":"Nuvalent, based in Cambridge, Massachusetts, and listed as NUVL, designs kinase inhibitors that are cleaner than their predecessors; zidesamtinib, its ROS1 inhibitor, was approved in July 2026 as Jideytro, and neladalkib, its ALK inhibitor, is next. Neladalkib is being tested in the ALKOVE-1 trial and a HER2-selective programme follows. OnCo links it to non-small-cell lung cancer and to the zidesamtinib and neladalkib drug records. Whether selectivity translates into fewer side effects and longer control than existing ROS1 and ALK drugs in routine use is the open question. Zidesamtinib has its own page.","asOf":"2026-09-04","links":[{"label":"Official website","url":"https://www.nuvalent.com"}],"tags":[],"related":[],"cancers":[],"sections":["targeted-therapy"],"technologies":[],"targets":[],"drugs":["zidesamtinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06765109","nct05118789"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Cambridge, MA","country":"US","companyType":"biotech","website":"https://www.nuvalent.com","ticker":"NUVL","investors":[],"funding":[]},"route":"/companies/nuvalent/","neighbours":{"section":[{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"drug":[{"id":"neladalkib","kind":"drug","name":"Neladalkib","route":"/drugs/neladalkib/"},{"id":"zidesamtinib","kind":"drug","name":"Zidesamtinib","route":"/drugs/zidesamtinib/"}],"trial":[{"id":"nct05118789","kind":"trial","name":"A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)","route":"/trials/nct05118789/"},{"id":"alkove-1","kind":"trial","name":"ALKOVE-1","route":"/trials/alkove-1/"},{"id":"nct06765109","kind":"trial","name":"Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC","route":"/trials/nct06765109/"}],"cancer":[{"id":"alk-positive-nsclc","kind":"cancer","name":"ALK-positive non-small-cell lung cancer","route":"/cancers/alk-positive-nsclc/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"ros1-positive-nsclc","kind":"cancer","name":"ROS1-positive non-small-cell lung cancer","route":"/cancers/ros1-positive-nsclc/"}],"company":[{"id":"bain-capital-life-sciences","kind":"company","name":"Bain Capital Life Sciences","route":"/companies/bain-capital-life-sciences/"},{"id":"deerfield-management","kind":"company","name":"Deerfield Management","route":"/companies/deerfield-management/"}],"roadmap":[{"id":"targeted-therapy-roadmap","kind":"roadmap","name":"Targeted therapy roadmap: imatinib → designed for resistance → the undruggable drivers fall","route":"/roadmaps/targeted-therapy-roadmap/"}]}}